Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2025Frontiers in EndocrinologyOpen Access

A glimpse into the pipeline of anti-obesity medication development: combining multiple receptor pathways

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChristine ParkEADA Business SchoolYKYushin KimKorea National University of TransportationSRSawye RayganiUniversity of San Diego

Discussion

Loading...

Member takes

Overview

This review highlights emerging agents for obesity treatment, suggesting improved efficacy through combination strategies.

Key Points

  • Recent advances in anti-obesity pharmacotherapy offer hope for patients living with obesity, improving treatment efficacy.
  • Obesity, a chronic metabolic disease, has seen an influx of emerging agents that show promise in addressing underlying causes.
  • The review discusses how combination strategies between different receptor pathways may enhance the effectiveness of obesity treatment.
  • Despite the effectiveness of metabolic bariatric surgery, anti-obesity medications represent a less invasive option worth exploring.

Cite This Study

Park et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3f31b076d99fa54ff0https://doi.org/10.3389/fendo.2025.1630199
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pharmacological management of obesity: Current landscape and emerging therapies2026
  2. 2Drugs Used in the Treatment of Obesity – A Systematic Review2026
  3. 3Recent Advancements in the Management of Obesity2024
  4. 4Bariatric surgery in the era of modern obesity pharmacotherapy2026
  5. 5ADVANCES IN OBESITY PHARMACOTHERAPY: CURRENT STATE AND FUTURE PERSPECTIVES2026